Physician profile
Thomas E Klein
NPI 1508886243
$1,837.76
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,611 · 2020: $226.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $361.94 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $357.79 | 2019 | |
| Glaxosmithkline, LLC. | $241.29 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.06 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $128.63 | 2019 | |
| Alk-Abello, INC | $122.68 | 2019 | |
| Genentech USA, INC. | $122.39 | 2019 | |
| Horizon Therapeutics Plc | $115.68 | 2019 | |
| Pharming Healthcare, INC. | $114.04 | 2019 | |
| Optinose US, INC. | $111.37 | 2019 | |
| Kaleo, INC. | $24.31 | 2019 | |
| Pfizer INC. | $7.58 | 2020 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.